DE3686343T2 - Pharmazeutische zubereitung zur anwendung fuer die anreicherung von knochenmasse. - Google Patents

Pharmazeutische zubereitung zur anwendung fuer die anreicherung von knochenmasse.

Info

Publication number
DE3686343T2
DE3686343T2 DE8686104562T DE3686343T DE3686343T2 DE 3686343 T2 DE3686343 T2 DE 3686343T2 DE 8686104562 T DE8686104562 T DE 8686104562T DE 3686343 T DE3686343 T DE 3686343T DE 3686343 T2 DE3686343 T2 DE 3686343T2
Authority
DE
Germany
Prior art keywords
application
pharmaceutical preparation
afflicted
human
bone measurement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8686104562T
Other languages
English (en)
Other versions
DE3686343D1 (de
Inventor
Potts, Jr
Robert M Neer
David M Slovik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24892318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3686343(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of DE3686343D1 publication Critical patent/DE3686343D1/de
Publication of DE3686343T2 publication Critical patent/DE3686343T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
DE8686104562T 1985-04-04 1986-04-03 Pharmazeutische zubereitung zur anwendung fuer die anreicherung von knochenmasse. Expired - Fee Related DE3686343T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72001885A 1985-04-04 1985-04-04

Publications (2)

Publication Number Publication Date
DE3686343D1 DE3686343D1 (de) 1992-09-17
DE3686343T2 true DE3686343T2 (de) 1993-01-28

Family

ID=24892318

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686104562T Expired - Fee Related DE3686343T2 (de) 1985-04-04 1986-04-03 Pharmazeutische zubereitung zur anwendung fuer die anreicherung von knochenmasse.

Country Status (12)

Country Link
US (1) US4698328A (de)
EP (1) EP0197514B1 (de)
JP (2) JPH0772138B2 (de)
AT (1) ATE79271T1 (de)
AU (1) AU599905B2 (de)
CA (1) CA1288695C (de)
DE (1) DE3686343T2 (de)
DK (1) DK172816B1 (de)
IE (1) IE59620B1 (de)
IL (1) IL78342A (de)
PH (1) PH23720A (de)
ZA (1) ZA862510B (de)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833125A (en) * 1986-12-05 1989-05-23 The General Hospital Corporation Method of increasing bone mass
DE3725319A1 (de) * 1987-07-30 1989-02-09 Biotechnolog Forschung Gmbh Pth-modifikationen und therapeutische zusammensetzungen, die sie enthalten und daraus bestehen
EP0386109A1 (de) * 1987-11-12 1990-09-12 Schering Corporation Knochenbildungssbeschleunigung durch gm-csf
JPH07110809B2 (ja) * 1987-11-18 1995-11-29 帝人株式会社 更年期障害の治療薬
IL89392A (en) * 1988-03-23 1993-02-21 Teva Pharmaceutical Ind Ltd Je Compositions for the treatment of osteoporosis in humans comprising 24, 25-dihydroxy-vitamin d3
US5602116A (en) * 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
CA1341408C (en) * 1988-08-02 2002-12-10 Charles W. Bishop Method for treating and preventing loss of bone mass
US5104864A (en) * 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
US4942036A (en) * 1988-08-25 1990-07-17 Blair Geho W Therapy by vesicle delivery to the hydroxyapatite of bone
DE4026146A1 (de) * 1990-08-17 1992-02-20 Biotechnolog Forschung Gmbh Mittregionale pth fragmente in kombination mit 1,25(oh)(pfeil abwaerts)2(pfeil abwaerts)(pfeil hoch)d(pfeil hoch)(pfeil abwaerts)3(pfeil abwaerts) bewirken einen anabolen effekt (calciumeinbau) auf den knochen
AU666838B2 (en) * 1990-12-13 1996-02-29 Genentech Inc. Compounds and compositions which inhibit bone resorption
US20040009958A1 (en) * 1991-01-08 2004-01-15 Bone Care International, Inc. Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2
US6538037B2 (en) 1991-01-08 2003-03-25 Bone Care International, Inc. Methods for preparation and use of 1α,24(S)-dihydroxyvitamin D2
US5693615A (en) * 1991-06-05 1997-12-02 The Procter & Gamble Company Therapeutic compositions for osteoinduction
SK74594A3 (en) * 1991-12-17 1995-01-12 Procter & Gamble Pharma Treatment for treating of osteoporosis
US5382658A (en) * 1992-04-03 1995-01-17 Allelix Biopharmaceuticals Inc. Stability-enhanced variants of parathyroid hormone
CA2098639A1 (en) * 1992-06-19 1993-12-20 K. Anne Kronis Bone stimulating, non-vasoactive parathyroid hormone variants
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
DE69332105T2 (de) * 1992-09-29 2003-03-06 Inhale Therapeutic Systems San Pulmonale abgabe von aktiven fragmenten des parathormons
US6024090A (en) 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US7448375B2 (en) 1993-01-29 2008-11-11 Aradigm Corporation Method of treating diabetes mellitus in a patient
TW303299B (de) * 1993-07-22 1997-04-21 Lilly Co Eli
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
MX9603936A (es) * 1994-03-07 1997-05-31 Inhale Therapeutic Syst Metodos y composiciones para el suministro pulmonar de insulina.
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6376479B1 (en) 1995-04-03 2002-04-23 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20020183288A1 (en) * 1995-04-03 2002-12-05 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US20040043971A1 (en) * 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6242434B1 (en) 1997-08-08 2001-06-05 Bone Care International, Inc. 24-hydroxyvitamin D, analogs and uses thereof
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US6503893B2 (en) 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
US6566353B2 (en) 1996-12-30 2003-05-20 Bone Care International, Inc. Method of treating malignancy associated hypercalcemia using active vitamin D analogues
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
PL336231A1 (en) 1997-02-13 2000-06-19 Bone Care International System for aimed therapeutic delivery of vitamin d compounds
US20030129194A1 (en) * 1997-02-13 2003-07-10 Bone Care International, Inc. Targeted therapeutic delivery of vitamin D compounds
EP0891779A1 (de) * 1997-06-19 1999-01-20 Roche Diagnostics GmbH Pharmazeutische Kombinationspräparate enthaltend Parathyroidhormon und Calcium- und/oder Phosphatverbindungen
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US6770623B1 (en) * 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
DZ2873A1 (fr) 1998-08-19 2003-12-15 Lilly Co Eli Procédé pour augmenter la dureté et la rigidité osseuse.
US20040033950A1 (en) * 2000-09-26 2004-02-19 Hock Janet M. Method of increasing bone toughness and stiffness and reducing fractures
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
JP4486256B2 (ja) * 1998-10-22 2010-06-23 ザ・ジェネラル・ホスピタル・コーポレイション 副甲状腺ホルモン（ＰＴＨ）および副甲状腺ホルモン関連ペプチド（ＰＴＨｒＰ）の生物活性ペプチドおよびペプチド誘導体
US6537965B1 (en) * 1998-11-25 2003-03-25 The General Hospital Corporation Amino-terminal modified parathyroid hormone (PTH) analogs
US7057012B1 (en) * 1998-12-31 2006-06-06 The General Hospital Corporation PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
WO2000039278A2 (en) * 1998-12-31 2000-07-06 The General Hospital Corporation Pth functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules
US6479474B2 (en) * 1999-07-08 2002-11-12 Wisconsin Alumni Research Foundation Dietary calcium as a supplement to vitamin D compound treatment of multiple sclerosis
WO2001021198A1 (en) * 1999-09-20 2001-03-29 Eli Lilly And Company Method for reducing the risk of cancer
WO2001023521A2 (en) * 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
WO2001023427A1 (en) 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
US7022815B1 (en) 1999-09-29 2006-04-04 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (PTH)
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
WO2002006218A2 (en) * 2000-07-18 2002-01-24 Bone Care International, Inc. STABILIZED 1α-HYDROXY VITAMIN D
DE60116520T2 (de) * 2000-10-10 2006-08-31 Microchips, Inc., Bedford Microchip-reservoir-vorrichtungen mit drahtloser übertragung von energie und daten
WO2003009804A2 (en) * 2001-07-23 2003-02-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
US20030119771A1 (en) * 2001-08-22 2003-06-26 Rompaey Luc Van Modulators of bone homeostasis identified in a high-throughput screen
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
EP1592434A4 (de) * 2003-01-24 2009-07-01 Gen Hospital Corp Konformationseingeschränkte parathormon (pth)-analoga mit lactam-brücken
EP2201960A1 (de) * 2003-03-19 2010-06-30 The General Hospital Corporation Konformationseingeschränkte Parathormone mit Alpha-Helix-Stabilisatoren
SI1622630T1 (sl) * 2003-05-07 2012-12-31 Osteologix A/S Stroncijeva kombinacije za profilakso/zdravljenje patologij hrustanca in/ali kosti
WO2005009358A2 (en) 2003-07-17 2005-02-03 The General Hospital Corporation Conformationally constrained parathyroid hormone (pth) analogs
WO2005016265A2 (en) * 2003-08-06 2005-02-24 Rhodia Inc. Method for promoting bone growth
EP1667689A1 (de) * 2003-09-19 2006-06-14 Pfizer Products Inc. Pharmazeutische zubereitungen und verfahren mit einer kombination von 2-alkylidene-19-nor-vitamin d derivaten und parathyroid hormon
JP4815752B2 (ja) 2004-04-01 2011-11-16 味の素株式会社 アミノ酸含有飲食品
AU2005244734A1 (en) 2004-05-13 2005-12-01 Alza Corporation Apparatus and method for transdermal delivery of parathyroid hormone agents
US7094775B2 (en) 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents
US20080076975A1 (en) * 2005-01-25 2008-03-27 Microchips, Inc. Method and implantable device with reservoir array for pre-clinical in vivo testing
CA2595457A1 (en) 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
CA2628945A1 (en) * 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
EP2054077A4 (de) * 2006-08-04 2010-10-13 Gen Hospital Corp Polypeptidderivate des parathyroidhormons (pth)
US8568737B2 (en) * 2007-08-01 2013-10-29 The General Hospital Corporation Screening methods using G-protein coupled receptors and related compositions
AU2009356227A1 (en) 2009-12-07 2012-06-21 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9492508B2 (en) 2010-05-13 2016-11-15 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
WO2012111852A1 (ja) * 2011-02-17 2012-08-23 帝人ファーマ株式会社 椎体骨折治療剤及びその評価方法
US9418415B2 (en) * 2014-02-05 2016-08-16 Shimadzu Corporation Trabecular bone analyzer
CN110236710A (zh) * 2018-03-09 2019-09-17 中日友好医院 一种促进植骨材料在牙种植上颌窦外提升术后成骨的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3956260A (en) * 1967-11-09 1976-05-11 Ciba-Geigy Corporation Hypocalcaemic peptides and processes for their manufacture
US4241051A (en) * 1977-11-04 1980-12-23 Christie Robert B Calcitonin
JPS55139320A (en) * 1979-04-16 1980-10-31 Teijin Ltd Bone metabolism regulator
DE3243358A1 (de) * 1982-11-24 1984-05-24 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose

Also Published As

Publication number Publication date
PH23720A (en) 1989-11-03
EP0197514B1 (de) 1992-08-12
ATE79271T1 (de) 1992-08-15
JPH07179358A (ja) 1995-07-18
ZA862510B (en) 1986-11-26
IE59620B1 (en) 1994-03-09
DK155686D0 (da) 1986-04-04
DE3686343D1 (de) 1992-09-17
AU5561686A (en) 1986-10-09
AU599905B2 (en) 1990-08-02
JPS6233A (ja) 1987-01-06
IL78342A (en) 1991-06-10
DK172816B1 (da) 1999-08-02
US4698328A (en) 1987-10-06
DK155686A (da) 1986-10-05
JPH0772138B2 (ja) 1995-08-02
CA1288695C (en) 1991-09-10
JP2531505B2 (ja) 1996-09-04
EP0197514A1 (de) 1986-10-15
IE860891L (en) 1986-10-04

Similar Documents

Publication Publication Date Title
DE3686343T2 (de) Pharmazeutische zubereitung zur anwendung fuer die anreicherung von knochenmasse.
ES2190244T3 (es) Uso de la hormona paratiroidea constituida por una secuencia de aminoacidos 1-34 de la hormona paratiroidea humana para reducir el riesco de fracturas oseas vertebrales y no vertebrales.
RU2224539C2 (ru) Заживление переломов с помощью аналогов пептида, подобного паратироидному гормону (ртнrр)
IT1241996B (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
ES2055845T3 (es) Composicion farmaceutica para el tratamiento de la osteoporosis.
HUP0003349A2 (hu) Mellékpajzsmirigy-hormon peptidanalógok, ezeket hatóanyagként tartalmazó gyógyászati készítmények és alkalmazásuk
IT1241997B (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
NO942241L (de)
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
ATE275419T1 (de) Pharmazeutisches kombinationspräparat aus parathormon und einem inhibitor der knochenresorption
BG100911A (en) Biophosphonic acids-sontaining wet-granulated form
DK183389A (da) Fremgangsmaade til fremstilling af en administrerings- og/eller doseringsform for medicinsk aktive materialer
ES2044947T4 (es) Metodo para fabricar una composicion farmaceutica para el tratamiento de la osteoporosis y otras enfermedades oseas.
PT1089968E (pt) Analogos de hormona tiroideia e metodos para a sua preparacao
ES2041647T3 (es) Metodo para producir un compuesto de oseinahidroxiapatita.
FR2684878B1 (fr) Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
KR920700224A (ko) 신규의 생리활성 펩티드 및 이를 유효성분으로서 함유한 칼슘대사 조절제
RU96100080A (ru) Лечение состояний, связанных с нарушением уровня паратгормона
IT1259140B (it) Formulazioni farmaceutiche per la somministraziane orale di calcitonina
TH48282A (th) การรักษาโรคของการให้ยาประกอบร่วมกันของโรคกระดูกพรุน

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings
8339 Ceased/non-payment of the annual fee